Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Creo Medical Group stock

CREO.L
GB00BZ1BLL44
A2DH40

Price

0.19
Today +/-
+0
Today %
+0 %

Creo Medical Group stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Creo Medical Group stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Creo Medical Group stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Creo Medical Group stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Creo Medical Group's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Creo Medical Group Stock Price History

DateCreo Medical Group Price
12/23/20240.19 undefined
12/20/20240.19 undefined
12/19/20240.17 undefined
12/18/20240.16 undefined
12/17/20240.17 undefined
12/16/20240.18 undefined
12/13/20240.17 undefined
12/12/20240.16 undefined
12/11/20240.14 undefined
12/10/20240.14 undefined
12/9/20240.15 undefined
12/6/20240.15 undefined
12/5/20240.15 undefined
12/4/20240.15 undefined
12/3/20240.16 undefined
12/2/20240.16 undefined
11/29/20240.16 undefined
11/28/20240.16 undefined
11/27/20240.16 undefined
11/26/20240.16 undefined
11/25/20240.16 undefined

Creo Medical Group Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Creo Medical Group, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Creo Medical Group from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Creo Medical Group’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Creo Medical Group. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Creo Medical Group’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Creo Medical Group’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Creo Medical Group’s growth potential.

Creo Medical Group Revenue, EBIT and net profit per share

DateCreo Medical Group RevenueCreo Medical Group EBITCreo Medical Group Net Income
2029e46.84 M undefined9.05 M undefined0 undefined
2028e32.84 M undefined-315,800.22 undefined0 undefined
2027e20.47 M undefined-8.02 M undefined-5.08 M undefined
2026e28.08 M undefined-13.33 M undefined-10.68 M undefined
2025e32.47 M undefined-19.04 M undefined-12.27 M undefined
2024e34.82 M undefined-24.34 M undefined-21.67 M undefined
202330.8 M undefined-24.8 M undefined-21.7 M undefined
202227.17 M undefined-30.76 M undefined-26.94 M undefined
202125.16 M undefined-29.91 M undefined-24.6 M undefined
20209.43 M undefined-23.48 M undefined-20.32 M undefined
201913,470 undefined-18.88 M undefined-15.91 M undefined
20180 undefined-17.66 M undefined-14.81 M undefined
20170 undefined-8.9 M undefined-7.77 M undefined
20160 undefined-1.87 M undefined-1.61 M undefined
20150 undefined-3.8 M undefined-3.33 M undefined
20140 undefined-2.88 M undefined-2.38 M undefined
20130 undefined-1.95 M undefined-1.7 M undefined

Creo Medical Group Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00000009252730343228203246
--------177.788.0011.1113.33-5.88-12.50-28.5760.0043.75
-------44.4444.0048.1550.0044.1246.8853.5775.0046.8832.61
00000004111315000000
-1-2-3-1-7-14-15-20-24-26-21-21-12-10-500
-100.0050.00-66.67600.00100.007.1433.3320.008.33-19.23--42.86-16.67-50.00--
80.7480.7480.8283.7483.7493.78125.84161.58170.38187.89313000000
-----------------
Details

Keystats

ⓘ

Revenue and Growth

The Creo Medical Group Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Creo Medical Group is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201320142015201520162017201820192020202120222023
                       
0.890.310.312.570.8213.6944.5981.0545.0943.5313.118.5
0.30.110.110.410.260.060.160.064.273.945.257.8
0.30.510.510.560.961.633.154.023.064.824.932.8
000000.090.30.736.818.59.338.1
00000.090.30.310.240.230.371.090.7
1.490.920.923.542.1415.7748.5186.0959.4761.1733.6937.9
0.140.130.130.20.240.330.911.33.388.610.189.1
000000000.51.732.122.1
000013.0514.858.48.40000
00000.010.010.310.8710.278.698.087.1
0000000018.2618.5619.5619.1
00000.0100.0100.591.851.71.3
0.140.130.130.20.270.351.232.1732.9939.4441.6538.7
1.631.041.043.742.4216.1249.7588.2692.46100.6175.3476.6
                       
2017.8917.8918.271.4480.71120.5150.38158181182400
6.197.947.9413.46019.8165.84115.11115.26149.45149.52180.9
-4.83-7.21-7.21-10.261.63-5.24-18.24-32.6-52.19-74.22-99.76-120.3
00000000-0.43-2.09-0.54-1.2
000000000000
1.380.750.753.221.6314.6547.7182.6662.8173.3249.459.8
0.150.170.170.240.330.520.740.922.463.544.282.5
0.10.120.120.250.420.660.763.924.035.183.62.4
0000.010.010.270.10.045.725.633.991.9
00000000002.252
0000.010.010.010.040.175.815.383.371.1
0.250.30.30.510.771.471.645.0618.0319.7417.489.9
0000.020.0200.390.546.545.186.075.2
0000000021.7921.4
000000003.090.590.380.3
0000.020.0200.390.5411.637.558.456.9
0.250.30.30.530.791.472.035.629.6627.2925.9316.8
1.631.041.043.752.4216.1249.7588.2692.46100.6175.3476.6
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Creo Medical Group provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Creo Medical Group's financial health and stability.

Assets

Creo Medical Group's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Creo Medical Group must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Creo Medical Group after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Creo Medical Group's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (k)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2013201420152015null2016201720182019202020212022
-1-2-2-3-3-1-7-14-15-20-24-26
000000000123
0000000000-10
0000001144-11
0000000-1-1-2-2-2
000000000000
0000000-1-2-2-3-4
-1-2-2-3-3-1-6-14-11-16-26-25
0000000-1-10-6-3
0000000-10-20-7-5
000000000-20-1-2
000000000000
0000000001,000-2,0000
2115502046490340
2115502046491310
-----------2.00-
000000000000
00022-1123036-35-1-30
-1.4-2.34-2.34-3.270-1.73-7.14-15.69-12.97-16.86-32.13-28.33
000000000000

Creo Medical Group stock margins

The Creo Medical Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Creo Medical Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Creo Medical Group.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Creo Medical Group's sales revenue. A higher gross margin percentage indicates that the Creo Medical Group retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Creo Medical Group's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Creo Medical Group's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Creo Medical Group's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Creo Medical Group. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Creo Medical Group's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Creo Medical Group Margin History

Creo Medical Group Gross marginCreo Medical Group Profit marginCreo Medical Group EBIT marginCreo Medical Group Profit margin
2029e49.68 %19.33 %0 %
2028e49.68 %-0.96 %0 %
2027e49.68 %-39.2 %-24.81 %
2026e49.68 %-47.48 %-38.03 %
2025e49.68 %-58.64 %-37.78 %
2024e49.68 %-69.91 %-62.25 %
202349.68 %-80.52 %-70.45 %
202248.3 %-113.2 %-99.14 %
202146.04 %-118.86 %-97.75 %
202042.79 %-249.07 %-215.46 %
201936.75 %-140,129.03 %-118,122.86 %
201849.68 %0 %0 %
201749.68 %0 %0 %
201649.68 %0 %0 %
201549.68 %0 %0 %
201449.68 %0 %0 %
201349.68 %0 %0 %

Creo Medical Group Stock Sales Revenue, EBIT, Earnings per Share

The Creo Medical Group earnings per share therefore indicates how much revenue Creo Medical Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Creo Medical Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Creo Medical Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Creo Medical Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Creo Medical Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Creo Medical Group Revenue, EBIT and net profit per share

DateCreo Medical Group Sales per ShareCreo Medical Group EBIT per shareCreo Medical Group Earnings per Share
2029e0.11 undefined0 undefined0 undefined
2028e0.08 undefined0 undefined0 undefined
2027e0.05 undefined0 undefined-0.01 undefined
2026e0.07 undefined0 undefined-0.03 undefined
2025e0.08 undefined0 undefined-0.03 undefined
2024e0.08 undefined0 undefined-0.05 undefined
20230.1 undefined-0.08 undefined-0.07 undefined
20220.14 undefined-0.16 undefined-0.14 undefined
20210.15 undefined-0.18 undefined-0.14 undefined
20200.06 undefined-0.15 undefined-0.13 undefined
20190 undefined-0.15 undefined-0.13 undefined
20180 undefined-0.19 undefined-0.16 undefined
20170 undefined-0.11 undefined-0.09 undefined
20160 undefined-0.02 undefined-0.02 undefined
20150 undefined-0.05 undefined-0.04 undefined
20140 undefined-0.04 undefined-0.03 undefined
20130 undefined-0.02 undefined-0.02 undefined

Creo Medical Group business model

Creo Medical Group PLC is a British medical technology company that was founded in 2003 and is based in Chepstow, Wales. The company specializes in the development and marketing of innovative medical devices. Creo Medical aims to improve the lives of healthcare professionals and patients by providing them with state-of-the-art technology. The company's business model focuses on research, development, and sales of innovative medical devices. Their goal is to provide doctors with the most advanced technology to facilitate their work. Creo Medical offers a wide range of devices for endoscopic surgery. They follow an asset-light model, outsourcing production to save costs and increase efficiency. Creo Medical was founded in 2003 by a team of professionals consisting of doctors and engineers. Their objective was to promote the development of cutting-edge technology for the medical industry and improve the treatment of patients worldwide. The company quickly gained momentum and received its first patent in 2014. Their product range includes endoscopes and electrosurgical devices for endoscopic surgery. Endoscopes are used to visualize the internal surfaces of the body through a flexible tube inserted through a small incision. This type of technology is used in surgery, particularly in gastrointestinal and gynecological areas. Electrosurgical devices are used in heart surgery and to prevent bleeding during operations. Creo Medical operates in various sectors where their products are utilized: 1. Gastroenterology: focusing on the diagnosis and treatment of digestive tract diseases. 2. Laparoscopic surgery: a surgical technique that uses a few small incisions to introduce surgical instruments into the body. 3. Gynecology: dealing with the diagnosis and treatment of diseases in the female reproductive system. 4. Urology: involving the treatment of diseases in the urinary tract and male reproductive system. Creo Medical serves multiple markets and recently announced the acquisition of Albyn Medical, a leading British manufacturer and distributor of medical devices. The company reported a 68% increase in revenue to £8.8 million in 2020, attributing the growth to growing demand for laparoscopic and gastroenterological products. Creo Medical's stock was listed on London's AIM in 2018. In conclusion, Creo Medical is a British medical technology company specializing in the development, manufacturing, and marketing of medical devices used in various medical fields. Their advanced technologies contribute to breakthroughs in surgery, making procedures more precise and gentle. Creo Medical has become a significant player in the British and international medical industry and will continue to play an important role in this sector. Creo Medical Group is one of the most popular companies on Eulerpool.com.

Creo Medical Group SWOT Analysis

Strengths

Creo Medical Group PLC possesses several strengths that give it a competitive edge in the market. These strengths include:

  • Strong portfolio of innovative medical devices
  • Advanced technology and patented products
  • Experienced and skilled management team
  • Strong financial position and steady revenue growth
  • Well-established brand and reputation

Weaknesses

Despite its strengths, Creo Medical Group PLC also faces certain weaknesses that hinder its growth and performance:

  • Limited global presence and market penetration
  • Dependence on key suppliers and partners
  • Relatively small size compared to major competitors
  • Somewhat narrow product range
  • Challenges in expanding distribution network

Opportunities

There are several opportunities in the market that Creo Medical Group PLC can capitalize on to accelerate its growth:

  • Increasing global demand for minimally invasive surgical devices
  • Rising healthcare expenditure and investment in medical technology
  • Expansion into emerging markets with untapped potential
  • Partnerships and collaborations for research and product development
  • Continued focus on innovation and new product launches

Threats

Despite the opportunities, Creo Medical Group PLC is not immune to certain threats that could impact its performance:

  • Intense competition from established players in the medical device industry
  • Regulatory challenges and compliance requirements
  • Potential disruptions in the supply chain
  • Economic downturns and fluctuating currency exchange rates
  • Technological advancements by competitors
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Creo Medical Group Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Creo Medical Group historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Creo Medical Group shares outstanding

The number of shares was Creo Medical Group in 2023 — This indicates how many shares 313.004 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Creo Medical Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Creo Medical Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Creo Medical Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Creo Medical Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Creo Medical Group.

Creo Medical Group shareholders

%
Name
Stocks
Change
Date
8.73815 % Canaccord Genuity Wealth Management36,014,293-3,288,7718/27/2024
8.15546 % M&G Investment Management Ltd.33,612,73224,184,23212/31/2023
5.68284 % Baillie Gifford & Co.23,421,83610,884,39512/31/2023
4.12445 % Amati Global Investors Limited16,998,915-455,06712/31/2023
3.90197 % AXA Investment Managers UK Ltd.16,081,9588,088,99712/31/2023
3.48823 % Development Bank of Wales Plc14,376,727-5,400,0003/8/2024
3.48798 % River Global Investors LLP14,375,69713,026,71712/31/2023
3.01441 % SVM Asset Management Limited12,423,9071,800,0005/13/2024
2.42630 % Creo Medical Group Employee Benefit Trust10,000,000012/31/2023
2.01418 % BlackRock Investment Management (UK) Ltd.8,301,45506/30/2024
1
2
3
4
5
...
10

Creo Medical Group Executives and Management Board

Mr. Craig Gulliford

Creo Medical Group Chief Executive Officer, Executive Director (since 2012)
Compensation 677,445

Mr. David Woods

Creo Medical Group Executive Director, Chief Commercial Officer (since 2020)
Compensation 611,019

Prof. Christopher Hancock

Creo Medical Group Chief Technology Officer, Executive Director
Compensation 513,764

Mr. Richard Rees

Creo Medical Group Chief Financial Officer, Executive Director (since 2016)
Compensation 513,394

Mr. Charles Spicer

(52)
Creo Medical Group Independent Non-Executive Chairman of the Board
Compensation 86,000
1
2

Creo Medical Group Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
M&G Stock
M&G
SupplierCustomer 0,20-0,12-0,490,45-0,01
Cenkos Securities Stock
Cenkos Securities
SupplierCustomer 0,50-0,330,260,61-0,02
Canaccord Genuity Group Stock
Canaccord Genuity Group
SupplierCustomer 0,530,890,790,28-0,18
1

Most common questions regarding Creo Medical Group

What values and corporate philosophy does Creo Medical Group represent?

Creo Medical Group PLC represents values such as innovation, integrity, and excellence. The company is dedicated to delivering cutting-edge medical solutions to improve patient outcomes. Creo Medical Group PLC follows a patient-centric approach, ensuring that their products and technologies meet the highest standards of quality and effectiveness. Their corporate philosophy emphasizes the importance of collaboration, research, and development to provide advanced therapeutic solutions in the field of endoscopy and minimally invasive surgery. With a strong focus on continuous improvement and customer satisfaction, Creo Medical Group PLC strives to contribute to the advancement of medical technology for the benefit of patients worldwide.

In which countries and regions is Creo Medical Group primarily present?

Creo Medical Group PLC is primarily present in various countries and regions around the world. Some of the key markets where the company operates include the United Kingdom, Europe, Asia-Pacific, and North America. With its global presence, Creo Medical Group PLC caters to a wide range of customers and investors across different geographical locations.

What significant milestones has the company Creo Medical Group achieved?

Creo Medical Group PLC has achieved significant milestones since its establishment. Some noteworthy achievements include the FDA clearance for their Speedboat RS2 device, allowing the company to enter the US market and expand its customer base. Additionally, Creo Medical Group PLC received CE Mark approval for its CROMA platform, enabling commercialization in the European market. The company also secured key partnerships and collaborations with renowned medical institutions and professionals, highlighting its commitment to innovation and development in the medical device sector. With these milestones, Creo Medical Group PLC has established itself as a leading player in the field, dedicated to improving patient outcomes through advanced technology.

What is the history and background of the company Creo Medical Group?

Creo Medical Group PLC, a leading medical device company based in the UK, was founded in 2003. The company specializes in the development and commercialization of advanced surgical instruments. Creo Medical has a strong focus on non-invasive surgical technologies that provide effective treatments with minimal patient discomfort and enhanced recovery. With a talented team of professionals, Creo Medical has achieved significant milestones in its history, including the successful launch of its flagship device, the CROMA™ Advanced Energy Platform. The company is committed to driving innovation in the medical field, working towards improving patient outcomes and revolutionizing surgical procedures globally. Creo Medical Group PLC continues to grow and establish a strong presence in the market through its dedication to research, development, and commercialization of cutting-edge medical devices.

Who are the main competitors of Creo Medical Group in the market?

The main competitors of Creo Medical Group PLC in the market are (insert competitor names here).

In which industries is Creo Medical Group primarily active?

Creo Medical Group PLC is primarily active in the medical technology industry.

What is the business model of Creo Medical Group?

The business model of Creo Medical Group PLC revolves around developing and commercializing medical devices for surgical endoscopy. Creo Medical specializes in advanced energy devices and aims to provide innovative solutions for minimally invasive procedures, such as radiofrequency ablation and microwave coagulation. By leveraging its proprietary technology, Creo Medical aims to enable healthcare professionals to improve patient outcomes, minimize complications, and reduce healthcare costs. With a focus on enhancing clinical capabilities and expanding its product portfolio, Creo Medical Group PLC continues to drive innovation in the medical device industry.

What is the P/E ratio of Creo Medical Group 2024?

The Creo Medical Group P/E ratio is -2.78.

What is the P/S ratio of Creo Medical Group 2024?

The Creo Medical Group P/S ratio is 1.73.

What is the Quality Investing of Creo Medical Group?

The Quality Investing for Creo Medical Group is 5/10.

What is the revenue of Creo Medical Group 2024?

The expected Creo Medical Group revenue is 34.82 M GBP.

How high is the profit of Creo Medical Group 2024?

The expected Creo Medical Group profit is -21.67 M GBP.

What is the business model of Creo Medical Group

Creo Medical Group PLC is a British medical technology company that specializes in the development and marketing of advanced medical technologies for endoscopy. The company was founded in 2003 and is headquartered in Chepstow, Wales.

What is the Creo Medical Group dividend?

Creo Medical Group pays a dividend of 0 GBP distributed over payouts per year.

How often does Creo Medical Group pay dividends?

The dividend cannot currently be calculated for Creo Medical Group or the company does not pay out a dividend.

What is the Creo Medical Group ISIN?

The ISIN of Creo Medical Group is GB00BZ1BLL44.

What is the Creo Medical Group WKN?

The WKN of Creo Medical Group is A2DH40.

What is the Creo Medical Group ticker?

The ticker of Creo Medical Group is CREO.L.

How much dividend does Creo Medical Group pay?

Over the past 12 months, Creo Medical Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Creo Medical Group is expected to pay a dividend of 0 GBP.

What is the dividend yield of Creo Medical Group?

The current dividend yield of Creo Medical Group is .

When does Creo Medical Group pay dividends?

Creo Medical Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Creo Medical Group?

Creo Medical Group paid dividends every year for the past 0 years.

What is the dividend of Creo Medical Group?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Creo Medical Group located?

Creo Medical Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Creo Medical Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Creo Medical Group from 12/24/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 12/24/2024.

When did Creo Medical Group pay the last dividend?

The last dividend was paid out on 12/24/2024.

What was the dividend of Creo Medical Group in the year 2023?

In the year 2023, Creo Medical Group distributed 0 GBP as dividends.

In which currency does Creo Medical Group pay out the dividend?

The dividends of Creo Medical Group are distributed in GBP.

All fundamentals about Creo Medical Group

Our stock analysis for Creo Medical Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Creo Medical Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.